A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to determine safety and activity of a novel anticancer agent in patients with metastatic non-small cell lung cancer who failed 2 or 3 prior systemic treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer

NCT01070927

Non-Squamous Non-Small Cell Lung Cancer

COMPLETED PHASE2

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

NCT02470065

Non Small Cell Lung Cancer

SUSPENDED PHASE2

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142

Non-Small Cell Lung Cancer

RECRUITING PHASE3

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

NCT02876081

SMALL CELL LUNG CARCINOMA

WITHDRAWN PHASE2

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NCT01470716

NSCLC Stage II NSCLC, Stage IIIA

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AG2037

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* presence of measurable, metastatic non-small cell lung cancer (histologically or cytologically confirmed at the time of original diagnosis)
* treatment failure (recurrence, disease progression, or intolerable toxicity) of 2 or 3 prior systemic treatments. (Note: no more than 3 prior systemic regimens for non-small cell lung cancer including adjuvant chemotherapy)
* capable of understanding the nature of the trial and willing to give written informed consent
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
* hemoglobin level of \>=9 g/dL, absolute granulocyte count of \>=1.5 \× 109/L, and platelet count of \>=100 \× 109/L
* adequate renal function, as documented by a serum creatinine level of \<=1.5 times the institutional upper limit of normal (ULN) and a measured or calculated creatinine clearance of \>=60 mL/min
* adequate liver function, as demonstrated by a total bilirubin level of \<=1.5 times ULN; levels of serum glutamate oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \<=2 times ULN. If the patient has liver involvement then AST and ALT should be \<=5 times ULN
* for men with partners of child-bearing potential and all women of childbearing potential, willingness to use adequate contraception or practice abstinence during the course of the study at least 18 years of age
* life expectancy estimated at greater than 12 weeks

Exclusion Criteria

* history of blood transfusion within the last 14 days
* need of concurrent administration of allopurinol
* history of radiotherapy or chemotherapy within 4 weeks (nitrosourea or mitomycin C within 6 weeks) of the anticipated first day of dosing (patient must be fully recovered from the acute effects of any prior chemotherapy or radiotherapy)
* any psychological or sociological condition, addictive disorder, or family problems that might preclude compliance with the protocol
* any unstable or severe intercurrent medical condition that in the opinion of the investigator might interfere with achievement of study objectives
* receipt of an investigational agent within 28 days before the anticipated first day of dosing (patient must have recovered from all acute effects of previously administered investigational agents)
* pregnant or breast-feeding
* previous treatment with GARFT inhibitors
* history of radiation therapy to more than 40% of the marrow space
* history of a malignancy (other than non-small cell lung cancer) except those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years
* active brain metastases (requiring treatment or progressing)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No